Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP8 | P22894 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.33 |
| ▸ | GRM3 | Q14832 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.30 |
| ▸ | FPR2 | P25090 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20806113 | 0.81 | MMP8 (0.38) | MMP8GAASMN1; SMN2PIK3CDFPR2 | |
| SCHEMBL24700130 | 0.78 | MMP8 (0.35) | MMP8GRM2GRM3PIK3CDFPR2 | |
| SCHEMBL12308387 | 0.76 | PIK3CD (0.40) | MMP8GRM2GRM3PIK3CD | |
| SCHEMBL4173669 | 0.76 | POLB (0.35) | — | |
| SCHEMBL13065932 | 0.76 | MMP8 (0.36) | MMP8GAASMN1; SMN2PIK3CDFPR2 | |
| SCHEMBL23168321 | 0.76 | CYP2C19 (0.41) | MMP8GRM2GRM3GAASMN1; SMN2 | |
| SCHEMBL12335922 | 0.76 | EPHX1 (0.41) | — | |
| SCHEMBL12308386 | 0.75 | CYP1A2 (0.37) | MMP8PIK3CDFPR2 | |
| SCHEMBL12308896 | 0.75 | ALDH1A1 (0.31) | — | |
| SCHEMBL14104999 | 0.74 | MMP8 (0.35) | MMP8PIK3CDFPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143413-B2 | Polycationized phospholipid derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2012-03-27 | — | — | US | disclosed |
| US-8017638-B2 | Isoxazole derivative and isothiazole derivative having inhibitory activity on 11β-hydroxysteroid dehydrogenase type 1 | SHIONOGI & CO., LTD. (JP) | 2011-09-13 | — | — | US | disclosed |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | SHIONOGI & CO., LTD. (JP) | 2009-05-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131491-A1 | ISOXAZOLE DERIVATIVE AND ISOTHIAZOLE DERIVATIVE HAVING INHIBITORY ACTIVITY ON 11(beta)-HYDROXYSTEROID DEHYDROGENASE TYPE I | HSD3B1, NR5A1, HSD11B1 | MMP8 2451/4885GRM2 1562/4885GRM3 813/4885 |
| US-20100094020-A1 | POLYCATIONIZED PHOSPHOLIPID DERIVATIVES | PHOSPHO1, PLTP, PTDSS2 | MMP8 4720/4885GRM2 2705/4885GRM3 2351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.